Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that while female pattern hair loss in young to middle-aged women was commonly associated with markers of hyperandrogenism and specific histopathological features, its exact causes and treatment remain unclear.

This study observed that trichoscopic patterns, such as yellow dots and honey comb patterns, correlate with the severity of androgenetic alopecia in Indian patients, highlighting trichoscopy's diagnostic and prognostic value.

This study found that patients with androgenetic alopecia had significantly higher COVID-19 severity compared to matched controls, suggesting a potential link between androgen pathways and disease severity. The authors suggest further research to validate this hypothesis and explore antiandrogen treatments for managing COVID-19 severity.

This study found that among male and female patients at a dermatology clinic, higher severity of androgenetic alopecia was statistically associated with lower sexual function scores, although the findings should be interpreted cautiously due to sample size and methodological limitations.

This study observed that hair density and thickness were significantly reduced across multiple scalp sites in South Korean women with hair loss, highlighting potential patterns that could aid in differentiating hair disorders.

This study found that female pattern hair loss was common in postmenopausal women, with body mass index being a significant associated factor.

This study found that the prevalence of androgenetic alopecia in Chinese men and women was lower than in Caucasians and similar to that in Koreans.

Combination of minoxidil and finasteride is more effective in increasing hair diameter than minoxidil alone for female-pattern hair loss.

The document explains how hair loss patterns in men and women, known as Androgenetic alopecia, are classified using the Hamilton-Norwood system for men and the Ludwig grade system for women.

This study found that 5% azelaic acid solution and 2% minoxidil solution both significantly increased hair density and shaft diameter in women with FPHL, with no significant differences between them.

This article reviews the classification systems for androgenetic alopecia and reports no new research findings.

This study concluded that intralesional lyophilized growth factor injections are safe and improve trichoscopic hair parameters and clinical scores in patients with female pattern hair loss.

In this study, a topical combination of Stemoxydine® and Resveratrol significantly increased hair density in women with female pattern hair loss after 12 weeks of use.

This study found that female pattern hair loss was present in 12.5% of PCOS patients examined, with most cases in younger women, highlighting early detection and management importance.

In this study, female androgenic alopecia (grade II or III on Ludwig's scale) was found to be common among Finnish women aged 63, and several markers of insulin resistance, along with paternal history of alopecia, were associated with an increased risk.

This randomized clinical trial found that both topical ethinylestradiol 0.01% combined with minoxidil 2% and minoxidil 2% alone were similarly effective in enhancing hair growth for female pattern hair loss, though minoxidil alone was better tolerated with fewer side effects over 24 weeks.

In this study, injecting two different concentrations of botulinum toxin A was found to be safe and effective for treating androgenetic alopecia in Egyptian men and women, with improvements in hair grade and vellus hair density observed over six months.

In this study, the Hamilton-Norwood subtype of female pattern hair loss was associated with early onset and polycystic ovary syndrome, while the Ludwig pattern was more common overall.

In this study, researchers examined women with androgenic alopecia in the Indian subcontinent and found varying patterns of hair loss, with inconclusive hormonal profiles but potentially useful hair pull tests and trichograms.

In this study, a 42-year-old female with female pattern hair loss experienced reduced hair fall, improved hair density, normalized scalp oiliness, and increased confidence after four months of homeopathic treatment personalized to her symptoms, nutritional supplementation, and GroHair therapy.

This study introduces ALUDWIG, an automated tool for assessing female androgenic alopecia severity from smartphone images, which may offer a more consistent alternative to current scoring methods like the Ludwig scale.

In this study, a 26-year-old woman with polycystic ovarian disease and advanced hair loss (Ludwig Grade III) showed reduced hair shedding and improved hair density after four sessions of platelet-rich plasma combined with microneedling, with no reported adverse effects.

In this study, a 26-year-old woman with polycystic ovarian disease and severe hair loss showed reduced hair shedding and improved hair density following four sessions of platelet-rich plasma combined with microneedling, with no adverse effects reported.

This study found that trichoscopy positively correlates with disease severity in both male and female patients with androgenetic alopecia, suggesting its usefulness in early diagnosis and assessment.

This article discusses androgenetic alopecia and reports no new clinical results.

Topical 5α-reductase inhibitor helps counteract hair loss and stabilize it.

In this study, trichoscopy was found to be an effective noninvasive tool for diagnosing female pattern hair loss at early stages, potentially eliminating the need for scalp biopsies.

This study suggests that a high frequency of androgenetic alopecia is associated with increased severity of COVID-19 in hospitalized patients.

This case report suggests that individualized homeopathic therapy with Carcinosin may benefit pediatric patients with alopecia areata by improving hair regrowth and psychological symptoms, as supported by standardized assessment tools.

In this clinical study, low-level laser therapy using the HANDI-DOME LASER device increased hair counts by 51% compared to controls, indicating its potential as a safe and effective treatment for androgenetic alopecia in women aged 18 to 60.